SCHEMBL15524800

SCHEMBL15524800

Cc1cnc(Nc2ccc(C3CCN(C(=O)OC(C)(C)C)CC3)nc2)nc1C(CC(N)=O)Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT4 P35916 6/20 0.46
▸ PRMT5 O14744 2/20 0.41
▸ CCNA2 P20248 2/20 0.41
▸ CDK2 P24941 2/20 0.41
▸ CDK9 P50750 2/20 0.41
▸ CCND3 P30281 2/20 0.41
▸ CCNK O75909 1/20 0.41
▸ CDK6 Q00534 1/20 0.41
▸ SYK P43405 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ CCNT1 O60563 1/20 0.40
▸ CCNA1 P78396 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ TP53 P04637 2/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ PTK2 Q05397 1/20 0.39
▸ CDK4 P11802 1/20 0.39
▸ CCND1 P24385 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15524519 0.93 FLT4 (0.43) FLT4PRMT5CCNA2CDK2CDK9
SCHEMBL15524430 0.91 STAT6 (0.46) CCNA2CDK2CDK9CCND3CCNK
SCHEMBL15524674 0.91 FLT4 (0.47) FLT4SYKKDRJAK3PTK2
SCHEMBL15524476 0.91 FLT4 (0.50) FLT4PRMT5CCNA2CDK2CDK9
SCHEMBL15512828 0.88 FLT4 (0.49) FLT4PRMT5CCNA2CDK2CDK9
SCHEMBL15524013 0.87 CCND3 (0.43) CCNA2CDK2CDK9CCND3CCNK
SCHEMBL15524788 0.85 JAK3 (0.47) FLT4KDRJAK2JAK3PTK2
SCHEMBL15524080 0.85 CCND3 (0.58) CCNA2CDK2CDK9CCND3CCNK
SCHEMBL15524390 0.85 JAK3 (0.42) CCNA2CDK2CDK9CCND3CCNK
SCHEMBL15524767 0.84 FLT4 (0.43) FLT4CCND3KDRJAK3CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9266864-B2 VEGFR3 inhibitors CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2016-02-23 — — US disclosed
US-20150225377-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2015-08-13 — — US disclosed
US-20140080798-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225377-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR FLT4 1/4885PRMT5 1226/4885CCNA2 457/4885
US-20140080798-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR FLT4 1/4885PRMT5 1424/4885CCNA2 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback